Sigma Planning Corp Has $296,000 Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sigma Planning Corp cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 62.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 715 shares of the company's stock after selling 1,177 shares during the period. Sigma Planning Corp's holdings in IDEXX Laboratories were worth $296,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Angeles Wealth Management LLC raised its position in shares of IDEXX Laboratories by 2.4% in the third quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company's stock valued at $545,000 after purchasing an additional 25 shares during the period. Cranbrook Wealth Management LLC grew its stake in IDEXX Laboratories by 7.0% in the 4th quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after buying an additional 25 shares during the last quarter. Perigon Wealth Management LLC raised its holdings in IDEXX Laboratories by 1.8% in the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after acquiring an additional 26 shares during the period. Summit Trail Advisors LLC lifted its position in IDEXX Laboratories by 3.3% during the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after acquiring an additional 26 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its holdings in IDEXX Laboratories by 4.0% during the third quarter. First Horizon Advisors Inc. now owns 704 shares of the company's stock valued at $356,000 after acquiring an additional 27 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IDXX has been the topic of a number of recent analyst reports. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday. Finally, Leerink Partners started coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 target price for the company. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average price target of $533.75.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Stock Performance

IDXX traded up $0.04 during trading on Monday, reaching $437.15. 690,976 shares of the company's stock were exchanged, compared to its average volume of 535,414. The company has a market capitalization of $35.55 billion, a P/E ratio of 40.97, a PEG ratio of 3.41 and a beta of 1.37. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The business has a 50 day moving average price of $435.79 and a 200 day moving average price of $450.78. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $580.18.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.